La Jolla Pharmaceutical Company Gets European Commission Approval for GIAPREZA

La Jolla Pharmaceutical Company (NASDAQ:LJPC) has announced it has received approval from the European Commission (EC) for GIAPREZA to treat refractory hypotension in adults with septic or other shock who are hypotensive.

As quoted in the press release:

“We are pleased with the European Commission’s approval of GIAPREZA and look forward to bringing this new treatment option to the many critically ill European patients suffering from septic or other distributive shock,” said George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla. “We are appreciative of the patients, families and dedicated critical care teams who made the development of GIAPREZA possible.”

The EC’s approval is based on data from the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Phase 3 study, which established the safety and efficacy of GIAPREZA in adults with septic or other distributive shock. The EC’s decision is applicable to the 28 European Union member countries. Approval will also be recognized in Iceland, Norway and Liechtenstein.

Click here to read the full press release.